Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 45430 | 4.365 |
09:34 ET | 41675 | 4.33 |
09:36 ET | 332326 | 4.33 |
09:38 ET | 39651 | 4.31 |
09:39 ET | 272857 | 4.295 |
09:41 ET | 68358 | 4.29 |
09:43 ET | 550581 | 4.275 |
09:45 ET | 18545 | 4.26 |
09:48 ET | 38278 | 4.285 |
09:50 ET | 59950 | 4.31 |
09:52 ET | 33282 | 4.32 |
09:54 ET | 10321 | 4.3257 |
09:56 ET | 26577 | 4.3275 |
09:57 ET | 5866 | 4.31 |
09:59 ET | 13315 | 4.305 |
10:01 ET | 12296 | 4.305 |
10:03 ET | 15284 | 4.31 |
10:06 ET | 35681 | 4.33 |
10:08 ET | 19314 | 4.325 |
10:10 ET | 20958 | 4.345 |
10:12 ET | 20024 | 4.35 |
10:14 ET | 10862 | 4.355 |
10:15 ET | 12284 | 4.355 |
10:17 ET | 30986 | 4.34 |
10:19 ET | 8343 | 4.35 |
10:21 ET | 5857 | 4.3589 |
10:24 ET | 29594 | 4.35 |
10:26 ET | 11964 | 4.345 |
10:28 ET | 37163 | 4.35 |
10:30 ET | 12923 | 4.345 |
10:32 ET | 10525 | 4.345 |
10:33 ET | 5532 | 4.355 |
10:35 ET | 5927 | 4.355 |
10:37 ET | 9585 | 4.35 |
10:39 ET | 6905 | 4.355 |
10:42 ET | 20390 | 4.37 |
10:44 ET | 11032 | 4.375 |
10:46 ET | 6218 | 4.375 |
10:48 ET | 8622 | 4.385 |
10:50 ET | 11862 | 4.39 |
10:51 ET | 18447 | 4.39 |
10:53 ET | 46934 | 4.37 |
10:55 ET | 11845 | 4.37 |
10:57 ET | 16831 | 4.35 |
11:00 ET | 3429 | 4.355 |
11:02 ET | 5731 | 4.365 |
11:04 ET | 400 | 4.365 |
11:06 ET | 2735 | 4.365 |
11:08 ET | 2391 | 4.37 |
11:09 ET | 27708 | 4.345 |
11:11 ET | 37802 | 4.33 |
11:13 ET | 19953 | 4.33 |
11:15 ET | 24064 | 4.33 |
11:18 ET | 5199 | 4.33 |
11:20 ET | 15485 | 4.345 |
11:22 ET | 7760 | 4.35 |
11:24 ET | 14093 | 4.335 |
11:26 ET | 1900 | 4.335 |
11:27 ET | 1800 | 4.335 |
11:29 ET | 1170 | 4.335 |
11:31 ET | 10000 | 4.335 |
11:33 ET | 7495 | 4.33 |
11:36 ET | 2008 | 4.335 |
11:38 ET | 162626 | 4.37 |
11:40 ET | 40672 | 4.375 |
11:42 ET | 9395 | 4.375 |
11:44 ET | 33598 | 4.385 |
11:45 ET | 2492 | 4.385 |
11:47 ET | 525227 | 4.39 |
11:49 ET | 34420 | 4.39 |
11:51 ET | 122 | 4.392 |
11:54 ET | 15090 | 4.395 |
11:56 ET | 3465 | 4.405 |
11:58 ET | 3000 | 4.4006 |
12:00 ET | 12475 | 4.41 |
12:02 ET | 7880 | 4.41 |
12:03 ET | 7863 | 4.415 |
12:05 ET | 2800 | 4.41 |
12:07 ET | 5436 | 4.415 |
12:09 ET | 14248 | 4.4 |
12:12 ET | 38008 | 4.39 |
12:14 ET | 18301 | 4.39 |
12:16 ET | 1470 | 4.395 |
12:18 ET | 21365 | 4.39 |
12:20 ET | 11433 | 4.38 |
12:21 ET | 7890 | 4.375 |
12:23 ET | 10731 | 4.39 |
12:25 ET | 3944 | 4.385 |
12:27 ET | 523 | 4.39 |
12:30 ET | 2000 | 4.3801 |
12:32 ET | 4770 | 4.385 |
12:34 ET | 2666 | 4.385 |
12:36 ET | 8835 | 4.38 |
12:38 ET | 3231 | 4.38 |
12:39 ET | 900 | 4.38 |
12:41 ET | 1750 | 4.385 |
12:43 ET | 2922 | 4.385 |
12:45 ET | 8275 | 4.37 |
12:48 ET | 2418 | 4.375 |
12:50 ET | 2014 | 4.37 |
12:52 ET | 44772 | 4.39 |
12:54 ET | 88564 | 4.39 |
12:56 ET | 21435 | 4.42 |
12:57 ET | 7106 | 4.41 |
12:59 ET | 8141 | 4.42 |
01:01 ET | 33201 | 4.415 |
01:03 ET | 5729 | 4.415 |
01:06 ET | 1400 | 4.41 |
01:08 ET | 1226 | 4.42 |
01:10 ET | 4232 | 4.42 |
01:12 ET | 90091 | 4.425 |
01:14 ET | 18672 | 4.415 |
01:15 ET | 5609 | 4.415 |
01:17 ET | 1614 | 4.42 |
01:19 ET | 19841 | 4.425 |
01:21 ET | 52740 | 4.42 |
01:24 ET | 12325 | 4.425 |
01:26 ET | 6950 | 4.42 |
01:28 ET | 3683 | 4.425 |
01:30 ET | 8118 | 4.435 |
01:32 ET | 19598 | 4.43 |
01:33 ET | 7186 | 4.44 |
01:35 ET | 1150 | 4.44 |
01:37 ET | 12810 | 4.44 |
01:39 ET | 135357 | 4.45 |
01:42 ET | 46735 | 4.455 |
01:44 ET | 4104 | 4.455 |
01:46 ET | 6884 | 4.455 |
01:48 ET | 37160 | 4.455 |
01:50 ET | 2844 | 4.46 |
01:51 ET | 3100 | 4.46 |
01:53 ET | 38082 | 4.46 |
01:55 ET | 6712 | 4.46 |
01:57 ET | 21349 | 4.445 |
02:00 ET | 30406 | 4.435 |
02:02 ET | 3513 | 4.43 |
02:04 ET | 3692 | 4.44 |
02:06 ET | 660 | 4.45 |
02:08 ET | 7891 | 4.44 |
02:09 ET | 11809 | 4.4301 |
02:11 ET | 3269 | 4.435 |
02:13 ET | 7561 | 4.445 |
02:15 ET | 729 | 4.45 |
02:18 ET | 2070 | 4.45 |
02:20 ET | 1310 | 4.45 |
02:22 ET | 141102 | 4.444 |
02:24 ET | 8154 | 4.44 |
02:26 ET | 2200 | 4.445 |
02:27 ET | 1800 | 4.44 |
02:29 ET | 15919 | 4.435 |
02:31 ET | 16029 | 4.435 |
02:33 ET | 12346 | 4.445 |
02:36 ET | 100 | 4.445 |
02:38 ET | 2114 | 4.445 |
02:40 ET | 6148 | 4.45 |
02:42 ET | 1520 | 4.445 |
02:44 ET | 4559 | 4.45 |
02:45 ET | 800 | 4.445 |
02:47 ET | 200 | 4.45 |
02:49 ET | 13884 | 4.445 |
02:51 ET | 4010 | 4.44 |
02:54 ET | 19482 | 4.43 |
02:56 ET | 12268 | 4.43 |
03:00 ET | 1400 | 4.43 |
03:02 ET | 100 | 4.435 |
03:03 ET | 1300 | 4.435 |
03:05 ET | 1690 | 4.435 |
03:07 ET | 23320 | 4.424 |
03:09 ET | 20667 | 4.43 |
03:12 ET | 17675 | 4.43 |
03:14 ET | 2021 | 4.425 |
03:16 ET | 8963 | 4.43 |
03:18 ET | 18067 | 4.435 |
03:20 ET | 9826 | 4.43 |
03:21 ET | 4235 | 4.4388 |
03:23 ET | 4068 | 4.435 |
03:25 ET | 5511 | 4.435 |
03:27 ET | 4647 | 4.435 |
03:30 ET | 4700 | 4.435 |
03:32 ET | 39962 | 4.435 |
03:34 ET | 4626 | 4.435 |
03:36 ET | 4381 | 4.435 |
03:38 ET | 14776 | 4.445 |
03:39 ET | 34207 | 4.435 |
03:41 ET | 19058 | 4.445 |
03:43 ET | 2646 | 4.44 |
03:45 ET | 6112 | 4.44 |
03:48 ET | 8287 | 4.45 |
03:50 ET | 14845 | 4.445 |
03:52 ET | 106576 | 4.445 |
03:54 ET | 86173 | 4.43 |
03:56 ET | 32399 | 4.435 |
03:57 ET | 72204 | 4.44 |
03:59 ET | 681859 | 4.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.4x | --- |
Edgewise Therapeutics Inc | 2.6B | -17.8x | --- |
Immunitybio Inc | 2.5B | -3.8x | --- |
CG Oncology Inc | 2.5B | -31.2x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.8x | --- |
IDEAYA Biosciences Inc | 2.6B | -14.5x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 1,936.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.